Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy

Hongzhen Cai; Man Li; Ruiyi Deng; Mopei Wang; Yanyan Shi

doi:10.1186/s40364-022-00413-0

Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy

Biomark Res. 2022 Aug 30;10(1):67. doi: 10.1186/s40364-022-00413-0.

Authors

Hongzhen Cai^{1

2}, Man Li^{1

2}, Ruiyi Deng^{1

2}, Mopei Wang³, Yanyan Shi⁴

Affiliations

¹ Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, 100191, People's Republic of China.
² Peking University Health Science Center, Beijing, 100191, People's Republic of China.
³ Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, 100191, People's Republic of China. wangmopei@bjmu.edu.cn.
⁴ Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, 100191, People's Republic of China. shiyanyan@bjmu.edu.cn.

Abstract

Gastric cancer is characterized by high morbidity and mortality worldwide. Early-stage gastric cancer is mainly treated with surgery, while for advanced gastric cancer, the current treatment options remain insufficient. In the 2022 NCCN Guidelines for Gastric Cancer, immunotherapy is listed as a first-line option for certain conditions. Immunotherapy for gastric cancer mainly targets the PD-1 molecule and achieves therapeutic effects by activating T cells. In addition, therapeutic strategies targeting other molecules, such as CTLA4, LAG3, Tim3, TIGIT, and OX40, have also been developed to improve the treatment efficacy of gastric cancer immunotherapy. This review summarizes the molecular biomarkers of gastric cancer immunotherapy and their clinical trials.

Keywords: Anti-PD-1; Biomarker; Checkpoint inhibitor; Gastric cancer; Immunotherapy.

Publication types

Review

Abstract

Publication types

Grants and funding